Ribavirin

證據等級: L5

預測適應症: 10 個

Ribavirin: From RNA Viral Infections (Hepatitis C, RSV) to Chronic Hepatitis B Virus Infection

One-Sentence Summary

Ribavirin is a guanosine-analogue antiviral historically used against RNA viruses such as hepatitis C virus (HCV) and respiratory syncytial virus (RSV), typically as part of combination regimens (e.g., peginterferon + ribavirin). The TxGNN model predicts it may also be effective for Chronic Hepatitis B Virus Infection, but the 50 cross-referenced clinical trials and 20 publications identified so far are almost entirely about ribavirin’s established use against HCV — direct evidence of anti-HBV activity is minimal, and the drug currently has no marketing authorisation in Denmark.

Quick Overview

Item	Content
Original Indication	Not available — no Denmark marketing authorisation on file (drug is not marketed); known historical use is against HCV/RSV (see mechanism section)
Predicted New Indication	Chronic Hepatitis B Virus Infection
TxGNN Prediction Score	99.86%
Evidence Level	L4
Denmark Market Status	Not Marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ribavirin is not available in this evidence pack (DrugBank query pending / data gap). Based on known pharmacology, ribavirin is a guanosine analogue that primarily inhibits inosine monophosphate dehydrogenase (IMPDH) and RNA-dependent RNA polymerase, and induces lethal mutagenesis in RNA viruses — mechanisms established for HCV and RSV.

Hepatitis B virus (HBV), however, is a DNA virus that replicates via reverse transcription and is not a traditional ribavirin target. Reviewing the evidence collected, the overwhelming majority of the identified literature and trials involve HBV/HCV co-infected patients, where ribavirin is used to treat the HCV component of the infection rather than HBV itself. Only one publication (PMID 10832679, “Is ribavirin treatment really effective for chronic hepatitis B?”) directly addresses ribavirin’s efficacy against HBV, and its abstract is not available in this pack.

In short, the mechanistic link between ribavirin and chronic HBV infection is weak and indirect. The high TxGNN score most likely reflects network-level association (shared “hepatitis” disease-class connections and frequent co-occurrence with HBV in the co-infection literature) rather than a validated direct antiviral mechanism against HBV.

Clinical Trial Evidence

Note: TxGNN-linked trials for this indication were reviewed for relevance. The great majority are graded C (low relevance) — they investigate ribavirin/peginterferon regimens in chronic hepatitis C, not hepatitis B, and appear to have been associated with this indication due to keyword overlap (“hepatitis”). No trial in the evidence pack directly tests ribavirin in HBV-infected patients.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00215865	Phase 3	Completed	600	PEGIntron + ribavirin dosing comparison in chronic hepatitis C (relapse after prior IFN therapy); not an HBV trial.
NCT01447420	Phase 4	Completed	129	Pegasys + Copegus (ribavirin) efficacy vs. IL28B expression in genotype 1 HCV; not HBV-related.
NCT01405027	Phase 4	Completed	197	Boceprevir + peginterferon + ribavirin compliance study in hepatitis C patients; not HBV-related.
NCT01655966	Phase 3	Unknown	80	Vitamin D add-on to peginterferon/ribavirin in hepatitis C genotype 4; not HBV-related.
NCT01830127	Phase 2	Completed	35	BI 207127 + faldaprevir + ribavirin pharmacokinetics in genotype 1b hepatitis C; not HBV-related.
NCT02493855	Phase 2	Completed	46	Ombitasvir/ABT-450/ritonavir + dasabuvir with ribavirin, viral kinetics in genotype 1a HCV; not HBV-related.
NCT01949168	Phase 2	Unknown	30	Boceprevir-based therapy for genotype 6 hepatitis C; not HBV-related.
NCT03261349	Phase 2	Unknown	21	Ledipasvir/sofosbuvir for HCV-associated B-cell lymphoma; not HBV-related.
NCT01220947	Phase 2	Completed	421	Danoprevir + ritonavir + Pegasys/Copegus in treatment-naive hepatitis C; not HBV-related.
NCT01598090	Phase 3	Completed	881	Peginterferon Lambda-1a + ribavirin + telaprevir vs. alfa-2a regimen in genotype-1 hepatitis C; not HBV-related.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10832679	2000	Unclassified	Journal of Gastroenterology	Title directly asks “Is ribavirin treatment really effective for chronic hepatitis B?” — the only publication addressing ribavirin’s direct anti-HBV efficacy; abstract not available in this data pack.
32664198	2020	Review	Viruses	Reviews HCV/HBV co-infection management; peginterferon + ribavirin recommended for the HCV component in co-infected, HCV-RNA-positive patients.
27433078	2016	Review	World Journal of Gastroenterology	Notes HBV persists even after direct-acting antiviral therapy and requires life-long treatment, unlike HCV which can be cured.
24659886	2014	Review	World Journal of Gastroenterology	Updates on treatment outcomes in dual chronic HCV/HBV infection; higher risk of liver disease progression in dual infection.
19669238	2009	Review	Hepatology International	Discusses viral interaction dynamics in dual HBV/HCV infection under treated vs. untreated settings.
17009938	2006	Review	Expert Review of Anti-infective Therapy	Reviews treatment options for chronic hepatitis B and C in children, including standardized regimens.
25232239	2014	Cohort	World Journal of Gastroenterology	IL28B polymorphism associated with SVR in HCV treated with peginterferon/ribavirin; relationship with HBV outcomes less clear (no consensus).
26284971	2015	Cohort	Current Opinion in Virology	IL28B genotype linked to treatment-induced and spontaneous viral clearance in HCV; relevance to HBV outcome discussed.
21538279	2011	Review	Seminars in Liver Disease	Reviews host genetic determinants of chronic HBV and HCV disease outcome.
18804888	2008	Review	Journal of Hepatology	Discusses ongoing challenges in treating HBV/HCV co-infection.

Denmark Market Information

Ribavirin currently has no marketing authorisation on file in Denmark (market status: Not Marketed; 0 authorisations recorded). No product, dosage form, or approved-indication data are available for this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack (a blocking data gap — SmPC warnings/contraindications retrieval — is flagged for follow-up before any S1 safety screening can proceed).

Conclusion and Next Steps

Decision: Hold

Rationale:

The mechanistic link is weak: ribavirin’s established antiviral mechanism targets RNA viruses, while HBV is a DNA virus replicating via reverse transcription.
Nearly all identified clinical trials concern ribavirin’s established use in hepatitis C (graded low-relevance to HBV); only one older publication directly questions ribavirin’s efficacy against HBV, with no abstract available.
A blocking data gap (SmPC warnings/contraindications) prevents even an initial (S1) safety evaluation.

To proceed, the following is needed:

TFDA/Danish SmPC warnings and contraindications (blocking gap, DG001)
Confirmed mechanism of action data via DrugBank (DG002)
Direct preclinical or clinical evidence of anti-HBV activity (the single directly relevant publication needs full-text review)
Re-triage of the “pending” relevance-graded trials and literature to confirm none provide direct HBV evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.